ne, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. INTEGRILIN should not be administered through the same intravenous line as furosemide.
INTEGRILIN may be administered in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. No incompatibilities have been observed with intravenous administration sets. No compatibility studies have been performed with PVC bags.
The bolus dose(s) of INTEGRILIN should be withdrawn from the 10-mL vial into a syringe. The bolus dose(s) should be administered by IV push.
Immediately following the bolus dose administration, a continuous infusion of INTEGRILIN should be initiated. When using an intravenous infusion pump, INTEGRILIN should be administered undiluted directly from the 100-mL vial. The 100-mL vial should be spiked with a vented infusion set. Care should be taken to center the spike within the circle on the stopper top.
INTEGRILIN is to be administered by volume according to patient weight. Patients should receive INTEGRILIN according to the following table:
INTEGRILIN Dosing Charts by Weight Patient Weight 180-mcg/kg Bolus Volume 2.0-mcg/kg/min
Infusion Volume 1.0-mcg/kg/min
Infusion Volume
(kg) (lb) (from 2-mg/mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial)
37–41 81–91 3.4 mL 2.0 mL/h 6.0 mL/h 1.0 mL/h 3.0 mL/h
42–46 92–102 4.0 mL 2.5 mL/h 7.0 mL/h 1.3 mL/h 3.5 mL/h
47–53 103–117 4.5 mL 3.0 mL/h 8.0 mL/h 1.5 mL/h 4.0 mL/h
54–59 118–130 5.0 mL 3.5 mL/h 9.0 mL/h 1.8 mL/h 4.5 mL/h
60–65 131–143 5.6 mL 3.8 mL/h 10.0 mL/h 1.9 mL/h 5.0 mL/h
66–71 144–157 6.2 mL 4.0 mL/h 11.0 mL/h 2.0 mL/h 5.5 mL/h
72–78 158–172 6.8 mL 4.5 mL/h 12.0 mL/h 2.3 mL/h 6.0 mL/h
79–84 173–185 7.3 mL 5.0 mL/h 13.0 mL/h 2.5 mL/h 6.5 mL/h
85–90 186–198 7.9 mL 5.3 mL/h 14.0 mL/h 2.7 mL/h 7.0 mL/h
91–96 199–212 8.5 mL 5.6 mL/h 15.0 mL/h 2.8 mL/h 7.5 mL/h
97–103 213–227 9.0 mL 6.0 mL/h 16.0 mL/h 3.0 mL/h 8.0 mL/h
104–109 228–240 9.5 mL 6.4 mL/h 17.0 mL/h 3.2 mL/h 8.5 mL/h
110–115 241–253 10.2 mL 6.8 mL/h 18.0 mL/h 3.4 mL/h 9.0 mL/h
116–121 254–267 10.7 mL 7.0 mL/h 19.0 mL/h 3.5 mL/h 9.5 mL/h
>121 >267 11.3 mL 7.5 mL/h 20.0 mL/h 3.7 mL/h 10.0 mL/h
HOW SUPPLIED
INTEGRILIN (eptifibatide) Injection is supplied as a sterile solution in 10-mL vials containing 20 mg of eptifibatide (NDC 0085-1177-01) and 100-mL vials containing either 75 mg of eptifibatide (NDC 0085-1136-01) or 200 mg of eptifibatide (NDC 0085-1177-02).
Vials should be stored refrigerated at 2°–8°C (36°–46°F). Vials may be transferred to room temperature storage2 for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a "DISCARD BY" date (2 months from the transfer date or the labeled expiration date, whichever comes first).
Do not use beyond the labeled expiration date. Protect from light until administration. Discard any unused portion left in the vial.
--------------------------------------------------------------------------------
2
Store at 25°C (77°F); excursions permitted to 15°–30°C (59
